{
    "id": "347830a8-8833-26b7-e063-6294a90a1f17",
    "indications": {
        "text": "hyoscyamine sulfate extended-release tablets effective adjunctive therapy treatment peptic ulcer . also used control gastric secretion , visceral spasm hypermotility spastic colitis , spastic bladder , cystitis , pylorospasm , associated abdominal cramps . may used functional intestinal disorders reduce symptoms seen mild dysenteries , diverticulitis , acute enterocolitis . adjunctive therapy treatment irritable bowel syndrome ( irritable colon , spastic colon , mucous colitis ) functional gastrointestinal disorders . also used adjunctive therapy treatment neurogenic bladder andmneurogenic bowel disturbances ( including splenic flexure syndrome neurogenic colon ) . hyoscyamine sulfate extended-release tablets indicated along morphine narcotics symptomatic relief biliary renal colic ; \u201c drying agent \u201d relief symptoms acute rhinitis ; therapy parkinsonism reduce rigidity tremors control associated sialorrhea hyperhidrosis . may used therapy poisoning anticholinesterase agents .",
        "doid_entities": [
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            },
            {
                "text": "cystitis (DOID:1679)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1679"
            },
            {
                "text": "pylorospasm (DOID:12072)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12072"
            },
            {
                "text": "diverticulitis (DOID:7475)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7475"
            },
            {
                "text": "irritable bowel syndrome (DOID:9778)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9778"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "neurogenic bladder (DOID:12143)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12143"
            },
            {
                "text": "acute rhinitis (DOID:10459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10459"
            },
            {
                "text": "rhinitis (DOID:4483)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4483"
            },
            {
                "text": "parkinsonism (DOID:0080855)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080855"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "may adjusted according conditions severity symptoms .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "hyoscyamine sulfate extended-release tablets , 0.375 mg white , capsule-shaped tablets . coded \u201c ap \u201d one side \u201c 115 \u201d . bottles 100 tablets ndc 75929-057-10 store controlled room temperature 20\u00b0-25\u00b0c ( 68\u00b0-77\u00b0f ) ; excursions permitted 15\u00b0-30\u00b0c ( 59\u00b0-86\u00b0f ) . please refer current usp . dispense tight , light-resistant containers defined usp/nf child-resistant closure . keep reach children also available : strength package size ndc hyoscyamine sulfate tablets , usp 0.125 mg 100 75929-055-10 hyoscyamine sulfate sublingual tablets 0.125 mg 100 75929-056-10 distributed : wallace pharmaceuticals inc. somerset , new jersey 08873-4120 \u00a92018 mylan pharmaceuticals inc wallace trademarks wallace pharmaceuticals inc. , mylan company in-1151-03 rev . 3/2018 printed usa 70011278",
    "adverseReactions": "glaucoma ; obstructive uropathy ( example , bladder neck obstruction due prostatic hypertrophy ) ; obstructive disease gastrointestinal tract ( achalasia , pyloroduodenal stenosis ) ; paralytic ileus , intestinal atony elderly debilitated patients ; unstable cardiovascular status acute hemorrhage ; severe ulcerative colitis ; toxic megacolon complicating ulcerative colitis ; myasthenia gravis .",
    "ingredients": [
        {
            "name": "HYOSCYAMINE SULFATE",
            "code": "F2R8V82B84",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        }
    ],
    "organization": "Pharma Packaging Solutions, LLC dba Tjopack LLC",
    "name": "Hyoscyamine",
    "effectiveTime": "20250506",
    "indications_original": "Hyoscyamine sulfate extended-release tablets are effective as adjunctive therapy in the treatment of peptic ulcer. They can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder andmneurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Hyoscyamine sulfate extended-release tablets are indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a \u201cdrying agent\u201d in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.",
    "contraindications_original": "Dosage may be adjusted according to the conditions and severity of symptoms.",
    "warningsAndPrecautions_original": "Hyoscyamine Sulfate Extended-Release Tablets, 0.375 mg are white, capsule-shaped tablets. They are coded \u201cAP\u201d on one side and \u201c115\u201d on the other.\n                  Bottles of 100 tablets          NDC 75929-057-10\n                  Store at controlled room temperature 20\u00b0-25\u00b0C (68\u00b0-77\u00b0F); excursions permitted to 15\u00b0-30\u00b0C (59\u00b0-86\u00b0F). Please refer to current USP.\n                  Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure.\n                  \n                     KEEP OUT OF REACH OF CHILDREN\n                  \n                  Also available as:\n                  \n                     \n                        \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                           \n                              \n                                 Dosage\n                                 \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Package\n                                 \n                                 Size\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                        \n                        \n                           \n                              Hyoscyamine Sulfate\n      \n\t\t\tTablets, USP\n     \n                           \n                           \n                              0.125 mg\n                           \n                           \n                              100\n                           \n                           \n                              75929-055-10\n                           \n                        \n                        \n                           \n                              Hyoscyamine Sulfate\n      \n\t\t\tSublingual Tablets\n     \n                           \n                           \n                              0.125 mg\n                           \n                           \n                              100\n                           \n                           \n                              75929-056-10\n                           \n                        \n                     \n                  \n                  Distributed by:\n  \nWallace Pharmaceuticals Inc.\n  \nSomerset, New Jersey 08873-4120\n  \n\u00a92018 Mylan Pharmaceuticals Inc\n \n                  WALLACE and \n  are trademarks of Wallace Pharmaceuticals Inc., a Mylan company\n \n                  IN-1151-03                 Rev. 3/2018\n                  Printed in USA\n                  70011278",
    "adverseReactions_original": "Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.",
    "drug": [
        {
            "name": "Hyoscyamine",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00424"
        }
    ]
}